Consensus Chongqing Zhifei Biological Products Co., Ltd.
Equities
300122
CNE100000V20
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.48 CNY | -1.59% |
|
+0.98% | -17.97% |
| 04-02 | Chongqing Zhifei Biological Products adjusts cooperation agreement with Merck & Co | RE |
| 01-12 | Zhifei Biological Products Unit's CA111 injection Enters Phase I Clinical Trials; Shares Up 3% | MT |
Evolution of the Average Target: Chongqing Zhifei Biological Products Co., Ltd.
Evolution of the Target Price: Chongqing Zhifei Biological Products Co., Ltd.
Changes in Analyst Recommendations: Chongqing Zhifei Biological Products Co., Ltd.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +60.08% | |||||
| +17.28% | |||||
| +3.89% | |||||
| +44.98% | |||||
| +47.72% | |||||
| +17.52% | |||||
| -10.02% | |||||
| +12.27% | |||||
| +5.54% | |||||
| +29.2% | |||||
| Average | +22.85% | |||||
| Weighted average by Cap. | +21.87% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| UBS |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300122 Stock
- Consensus Chongqing Zhifei Biological Products Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition